Chauhan et al. [136] showed that melflufen is (1) 10 times more active against hematological cancer cells than melphalan; (2) blocks the migration of MM cells and inhibits tumor-associated angiogenesis; (3) induces DNA damage associated with γ-H2A histone family member X (γ-H2AX) and p53 induction; and (4) is associated with caspase activation and poly-ADP ribose polymerase (PARP) cleavage via melflufen-induced apoptosis. This evidence concerns the gene TP53 and Miyoshi myopathy.